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Executive Summary 
The rising cost of prescription drugs is consuming an ever-larger portion of limited funds for basic health 
care and other important services in Washington state.  At the same time, there are almost one million 
Washingtonians who go without any prescription drug coverage, including the uninsured and the elderly.  
 
During the 2002 legislative session, prescription drug legislation that would have saved Washington state 
millions on prescription drugs and extended prescription drug savings to seniors and the uninsured was 
blocked by heavy lobbying from the pharmaceutical industry. One of the arguments raised against the 
legislation was that lower prescription drug prices would create a hostile environment for biotech 
research. However, the evidence shows that the biotech industry can continue to thrive in our state 
alongside lower drug prices. 
 
Allowing our state to be a wise consumer and to use its market power to rein in prescription drug costs is 
a sensible, near-term solution to skyrocketing health costs and will allow expanded access to prescription 
drugs.  
 
1. Fair drug prices will not cause biotech firms to leave the state. 
 
• Biotech companies make location decisions based on the presence of strong research institutions, 
venture capital, human capital, and overall quality of life. 
• Prescription drug legislation to make drugs more affordable in one state does not translate into a 
hostile environment for biomedical research in that state. 
• The global market for prescription drugs determines profits for the bio-technology and phamaceutical 
industries. 
 
2. State government has a responsibility to prioritize spending and strive for efficiency.  
 
• Prescription drug costs are consuming scarce dollars needed for other important programs and 
populations. 
• Meanwhile, many state residents have no prescription drug coverage, leading to poorer health 
outcomes and ultimately costing the state even more for expensive emergency room treatment. 
• Two problems – cost and access – can be addressed with one solution – smarter shopping.  
 
1. Fair drug prices will not cause biotech firms to leave the state. 
Biotech companies make location decisions based on the presence of 
strong research institutions, venture capital, human capital, and overall 
quality of life. 
• According to a major report on biotechnology growth, the two key determinants of biotech location 
are:  
• the existence of strong research institutions that attract talented scholars and receive National 
Institutes of Health funding, and 
• the availability of local venture capital.1   
As the Washington Technology Centers explains, “Because there is such a strong tie between the 
investors and the management of a company…[h]aving qualified and willing investors and investment 
institutions near the entrepreneurs is…key to growth in entrepreneurial companies”.2 Thus it is far more 
likely that Washington’s biggest draws to the biotech industry are the University of Washington and the 
venture capital groups already headquartered here, not the high prices of prescription drugs. 
• The chief financial officer of ZymoGenetics, a biotech company located in Seattle, claims that venture 
capitalists are focused on a slew of large national concerns, including “the bear market, a string of 
high-profile clinical-trial failures and a perceived shift toward more caution at the U.S. Food and Drug 
Administration”.3 
• According to a report called “Ten Steps to a High Tech Future,” the top five things metropolitan areas 
like Seattle can do to attract high tech firms are: 
1. Understand the region’s high tech firms and competitive advantages (e.g. by investigating 
workforce needs and location preferences); 
2. Invest in human capital (e.g. by funding job training and career opportunities); 
3. Create a research development presence (e.g. by investing in higher education); 
4. Invest in physical capital (e.g. by building roads, telecommunications capacity and infrastructure); 
and 
5. Invest in quality of life (e.g. by developing transportation, housing, the arts and ensuring a clean 
environment ).4 
 
Prescription drug legislation to make drugs more affordable in one state 
does not translate into a hostile environment for biomedical research in 
that state.  
• Well over half of all U.S. states have enacted or are considering some sort of prescription drug 
legislation.5  
• California implemented a preferred drug list for its Medicaid program that is much stricter than the 
one proposed for Washington state. California’s biotech industry is flourishing, with three of the 
top nine biotech firms in the nation located there, including Amgen, a powerhouse biotech with 
1999 sales four times higher than its leading competitor.6  
• Washington’s biotech industry is also faring very well.  In 1999, the biotech industry in 
Washington had an average firm profit margin of 12.5%, well above that of the general 
manufacturing, semiconductor, and software industries.7   
 
 
 
2 
The global market for prescription drugs determines profits for the bio-
technology and pharmaceutical industries. 
• Washington state’s share of the international drug market is tiny, accounting for only 1.7% 
percent of the total US prescription drug market and only 7/10 of 1% of total global sales. 8,9   
• Global sales of Prilosec were $6.1 billion in 2000.10  Washington state spent $15.5 million on this 
drug during the same year, accounting for only ¼ of 1% of global sales.11  
• Meanwhile, the pharmaceutical industry is the most profitable in the world, outpacing average 
profits for all Fortune 500 companies by 3-5 times over the past decade and spending 250% 
more on sales, marketing, and general administration than on research and development.12 
 
 
2. State government has a responsibility to prioritize spending and 
strive for efficiency. 
 
Prescription drug costs are consuming scarce dollars needed for other 
important programs and populations. 
• An almost 600% increase in Department of Social and Human Services DSHS spending on 
prescription drugs since 1997 threatens to consume funding for a broad range of agency 
services, including juvenile rehabilitation, child protective services, assistance for aging and 
disabled adults, cash and food assistance programs, and alcohol and substance abuse 
prevention and treatment.13 
• Prescription drugs account for around 25% of all DSHS health spending, or over $800 million per 
biennium. 14,15  Drug spending for DSHS programs is expected to increase by 34% over the next 
two years, drastically outpacing the costs of any other factor, benefit, or caseload.16   
• In 2000, Washington state agencies spent over $85.4 million on just nine name-brand drugs. 
Nearly half this spending was for just two drugs: Zyprexa and Prilosec.17 
• Continually increasing prescription drug spending makes it more difficult to expand access to 
health care and necessary prescription drugs to seniors and the uninsured.  
 
Meanwhile, many state residents have no prescription drug coverage, 
leading to poorer health outcomes and ultimately costing the state even 
more for expensive emergency room treatment.  
• While the state is spending more each year on prescription drugs, there are 644,000 
Washingtonians who do not have health insurance or prescription drug coverage. There are an 
additional estimated 200,000 elderly without a prescription drug health benefit, which means they 
must pay for all their drug costs out-of-pocket.18  
• At least 30% of those without drug coverage cannot afford to fill a needed prescription.19  
• Those who cannot afford prescription drugs often skip doses or forego filling a prescription even 
for a life threatening condition, which can lead to poorer health, higher future costs and even 
avoidable death.20  
• When people are uninsured, they do not get the care they need, or they delay care to the point 
where minor health concerns become major health problems. The uninsured turn up in already 
overburdened emergency rooms and are unable to pay the bill, but their care is not free. It is 
picked up by providers, employers, the insured and taxpayers in the form of higher premiums and 
taxes. 
3 
• While implementing fair drug pricing will not hurt the biotech industry, inaction on this item will 
force the state to cut health budgets and enrollment in health programs, creating a ripple effect 
that does not end until it hurts taxpayers and the state economy. 
  
Two problems – cost and access – can be addressed with one solution – 
smarter shopping. 
• By being a better consumer, Washington state can help its residents.  Only by evaluating the 
benefits and costs of various and competing prescription drugs can Washington state insure that 
taxpayers and patients are getting quality outcomes in return for each dollar. By demanding that 
better health outcomes, not new health products, are the focus, we can insure more effective, 
cost-efficient care.  
• The money saved through shopping smarter and negotiating lower drug prices for currently 
covered groups will make it possible to expand necessary health and prescription drug coverage 
to many of the uninsured. 
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